Evidence map›Paper›PMID 41732008›Full record

ArticleFuture oncology (London, England)2026

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.

Evan Y Yu, Christian Gratzke, Mauricio Burotto, Alison Y Zhang, Eric Lévesque, Francisco Ortega, Avivit Peer, Donald Vile, Zheng Hong Chen, Yue Song and 6 more

2 registry-linked trialsAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06136624 phase3recruitingnot on this map

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2023 to 2030Enrolled1,310ConditionsProstate Cancer MetastaticArmsOpevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate
NCT06136650 phase3recruitingnot on this map

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2023 to 2030Enrolled1,314ConditionsMetastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic NeoplasmsArmsOpevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Evan Y YuMedical Oncology, Fred Hutchinson Cancer Center, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-1510-8044
Christian GratzkeUrology, University Hospital Freiburg, Freiburg, Germany.
Mauricio BurottoMedical Oncology, Bradford Hill Clinical Research Center, Universidad Finis Terrae, Santiago, Chile.
Alison Y ZhangMedical Oncology, MQ Health Clinical Trials Unit, Macquarie University, Sydney, Australia.
Eric LévesqueFaculty of Medicine, CHU de Québec, Department of Medicine, Université Laval, Québec, QC, Canada.
Francisco OrtegaMedical Oncology, Clinica Universidad Catolica Del Maule-Oncology, Talca, Chile.
Avivit PeerOncology Institute, Rambam Health Care Campus, Haifa, Israel.
Donald VileMedical Oncology, Blue Ridge Cancer Care, Roanoke, VA, USA.
Zheng Hong ChenMSD China, Beijing, China.
Yue SongMerck Research Laboratories Oncology, Merck & Co., Inc., Rahway, NJ, USA.
Charles SchlossMerck Research Laboratories Oncology, Merck & Co., Inc., Rahway, NJ, USA.
Jelena TodoricMerck Research Laboratories Oncology, Merck & Co., Inc., Rahway, NJ, USA.
Chris GarrattOncology Development, Orion Pharma, Espoo, Finland.
Christian PoehleinMerck Research Laboratories Oncology, Merck & Co., Inc., Rahway, NJ, USA.
Emmanuel S AntonarakisTranslational Research, Masonic Cancer Center, Genitourinary Oncology, University of Minnesota, Minneapolis, MN, USA.
Karim FizaziDepartment of Medical Oncology, Centre Oscar Lambret, University of Paris Saclay, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options for metastatic castration-resistant prostate cancer (mCRPC) include androgen receptor pathway inhibitors (ARPIs), taxanes, radium-223, Lu-PSMA, poly (ADP-ribose) polymerase inhibitors, and immunotherapy in select patients. Resistance to ARPIs and hormone-based therapies has been associated with AR-ligand-binding domain mutations that can lead to promiscuous stimulation by other steroid hormones. There is a need to explore alternative targets and develop next-generation ARPIs or combination therapies that overcome this resistance. We describe the rationale and design of the randomized phase III trials OMAHA-003 (NCT06136624) and OMAHA-004 (NCT06136650), which will evaluate the efficacy and safety of opevesostat, a steroidogenesis inhibitor, versus ARPI switch in previously treated mCRPC. Results may support opevesostat as a potential new treatment option for mCRPC.

Indexed as

BenzimidazolesProstatic Neoplasms, Castration-ResistantSteroid Synthesis InhibitorsAndrostadienesClinical Trials, Phase III as TopicHumansMaleNeoplasm MetastasisRandomized Controlled Trials as Topic3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-dieneAndrostadienesBenzimidazolesSteroid Synthesis InhibitorsARPIchemotherapyCYP11A1Metastatic castration-resistant prostate canceropevesostatsteroidogenesis inhibitor

Identifiers

PMID41732008
PMCPMC12977254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.